MARKET

IOVA

IOVA

Iovance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.75
+1.01
+3.40%
Opening 14:28 04/08 EDT
OPEN
29.86
PREV CLOSE
29.74
HIGH
31.16
LOW
29.35
VOLUME
493.63K
TURNOVER
--
52 WEEK HIGH
38.92
52 WEEK LOW
10.15
MARKET CAP
3.89B
P/E (TTM)
-19.3835
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IOVA stock price target is 40.00 with a high estimate of 60.00 and a low estimate of 35.00.

EPS

IOVA News

More
  • My Top Biotech Stocks to Buy in the Market Crash
  • MotleyFool.com · 1d ago
  • Iovance Biotherapeutics Option Alert: Apr 17 $30 Calls Sweep (43) near the Ask: 814 @ $3.701 vs 5723 OI; Earnings 5/5 After Close [est] Ref=$28.0925
  • Benzinga · 6d ago
  • Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA)
  • Insider Monkey · 03/27 19:55
  • Cowen bullish on Iovance Biotherapeutics; shares up 4% premarket
  • Seeking Alpha - Article · 03/25 12:51

Industry

Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+2.64%

Hot Stocks

Symbol
Price
%Change

About IOVA

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
More

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.